Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100740 | 0.79 | HTR1A (0.45) | MMP12ADRB1PARP1ADRB2SMYD3 | |
| SCHEMBL16746129 | 0.75 | MMP12 (0.43) | MMP12ADRB1KDM5BPARP1ADRB2 | |
| SCHEMBL27051279 | 0.72 | ADRB1 (0.36) | MMP12ADRB1KDM5BPARP1ADRB2 | |
| SCHEMBL16746139 | 0.71 | ALDH1A1 (0.37) | HTR1ADRD2 | |
| SCHEMBL16746138 | 0.71 | KIF11 (0.38) | ADRB1KDM5BADRB2HTR1A | |
| SCHEMBL10215347 | 0.71 | ADRB1 (0.65) | ADRB1ADRB2DRD2 | |
| SCHEMBL19697171 | 0.71 | HTR1A (0.41) | MMP12ADRB1PARP1ADRB2SMYD3 | |
| SCHEMBL14680984 | 0.71 | ADRB2 (0.54) | ADRB1ADRB2 | |
| SCHEMBL16746136 | 0.70 | XIAP (0.36) | — | |
| SCHEMBL8301820 | 0.69 | MMP12 (0.50) | MMP12PARP1PDE3BPDE3ASMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148372-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148372-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | MMP12 4382/4885ADRB1 2406/4885KDM5B 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.